NYU School of Medicine
2014 Clinician Scientist Development Award in Myasthenia Gravis and Related Disorders of the Neuromuscular Junction Cosponsored by the American Academy of Neurology, the American Brain Foundation and the Myasthenia Gravis Foundation of America
Target brain disease(s): Myasthenia Gravis
Project goal: Identify new antibodies in myasthenia gravis and how they cause disease.
Project description: Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness and rapid fatigue of muscles under the patient’s voluntary control. Antibodies, or molecules that bind and tag other molecules, normally function as part of the human defense system but in some disorders, including myasthenia gravis, the body’s own molecules are recognized as foreign and destroyed. This research involved identifying new antibodies in myasthenia gravis and how they cause disease. Identifying these new antibodies can help develop diagnostic tools for myasthenia gravis and identify new molecular pathways that may cause disorders of the neuromuscular junction.
Funding: Received $130,000 in research funds.